SCHEMBL12436829

SCHEMBL12436829

CC(CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)N(C)c1ccc([N+](=O)[O-])c2nonc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OSBP P22059 4/20 0.59
RORC P51449 3/20 0.59
OSBP2 Q969R2 2/20 0.59
USP2 O75604 1/20 0.59
LMNA P02545 1/20 0.59
ABCB1 P08183 1/20 0.59
CYP46A1 Q9Y6A2 1/20 0.59
NR1H3 Q13133 6/20 0.57
NPC1L1 Q9UHC9 3/20 0.57
DHCR24 Q15392 1/20 0.57
GRIN1 Q05586 2/20 0.57
GRIN2A Q12879 2/20 0.57
CRYAB P02511 1/20 0.55
HMGCR P04035 1/20 0.55
ITGB3 P05106 1/20 0.55
ITGAV P06756 1/20 0.55
SREBF2 Q12772 1/20 0.55
GRIN2B Q13224 1/20 0.54
EPHA2 P29317 1/20 0.54
NR1H2 P55055 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17693794 0.95 OSBP (0.60) OSBPRORCOSBP2USP2LMNA
SCHEMBL17696316 0.91 OSBP (0.63) OSBPRORCOSBP2USP2LMNA
SCHEMBL1542632 0.89 USP2 (0.61) OSBPRORCOSBP2USP2LMNA
SCHEMBL1397890 0.86 OSBP (0.58) OSBPRORCOSBP2USP2LMNA
SCHEMBL1542841 0.82 ATIC (0.48) OSBPRORCOSBP2USP2LMNA
SCHEMBL29420066 0.82 DHCR24 (0.56) OSBPRORCOSBP2USP2LMNA
SCHEMBL19625268 0.82 DHCR24 (0.56) OSBPRORCOSBP2USP2LMNA
SCHEMBL4142848 0.80 POLA1 (0.54) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL9788710 0.78 OSBP (0.89) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL29222667 0.77 OSBP (0.80) OSBPRORCOSBP2USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180112245-A1 METHOD AND COMPOSITION FOR BIOCATALYTIC PROTEIN-OLIGONUCLEOTIDE CONJUGATION AND PROTEIN-OLIGONUCLEOTIDE CONJUGATE THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2018-04-26 US disclosed
US-20160109469-A1 METHOD OF MEASURING LIPOPROTEIN'S CAPACITY TO ACCEPT CHOLESTEROL SYSMEX CORPORATION (JP) 2016-04-21 US disclosed
US-20110177156-A1 Sterol-Modified Amphiphilic Lipids THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-07-21 US disclosed
WO-2009064696-A1 STEROL-MODIFIED AMPHIPHILIC LIPIDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110177156-A1 Sterol-Modified Amphiphilic Lipids SREBF1, SREBF2, SGMS1 OSBP 16/4885RORC 346/4885OSBP2 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.